Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 306 participants.
Also called NCT01524289
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 306 participants
- Sponsor
- Registry
-
NCT01524289 -
2011-004525-27
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01524289. Randomized; double masking; primary purpose treatment. Start 2012-02-03 (actual); primary completion 2014-02-12 (actual). Results posted on 2019-08-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)
- Acronym
- REALIZE
- Condition
- Hyperlipoproteinemia Type II
- Condition
- Hypercholesterolemia, Familial
- Intervention (Drug)
- Anacetrapib
- Intervention (Drug)
- Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01524289- Content hash
a2f5b1927c808a1a769a016d6195f9fa19793f0e516ee545af05f898642a8bc9